Ocrelizumab: a new milestone in multiple sclerosis therapy-Reference-Cited by-同舟云学术

Ocrelizumab: a new milestone in multiple sclerosis therapy

Published:2018-01 Issue: Volume:11 Page:175628641877302
ISSN:1756-2864
Container-title:Therapeutic Advances in Neurological Disorders
language:en
Short-container-title:Ther Adv Neurol Disord

Author:

Mulero Patricia¹,Midaglia Luciana¹,Montalban Xavier²

Affiliation:

1. Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Barcelona, Spain

2. Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Edif. Antiga EUI, Pl 2, Barcelona, 08035, SpainDivision of Neurology, University of Toronto, 190 Elizabet Street R. Fraser Elliott Building, 3-805, Toronto, ON, Canada

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology,Pharmacology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1756286418773025

Reference22 articles.

1. B cells and multiple sclerosis

2. Antibody-independent functions of B cells: a focus on cytokines

3. Oligoclonal IgG Bands in Cerebrospinal Fluid

4. Defining high, medium and low impact prognostic factors for developing multiple sclerosis

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disclosing the Novel Protective Mechanisms of Ocrelizumab in Multiple Sclerosis: The Role of PKC Beta and Its Down-Stream Targets;International Journal of Molecular Sciences;2024-08-16

2. The cost-utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran;Expert Review of Pharmacoeconomics & Outcomes Research;2024-08-08

3. Engineering antigen-presenting cells for immunotherapy of autoimmunity;Advanced Drug Delivery Reviews;2024-07

4. Multiple Sclerosis: Immune Cells, Histopathology, and Therapeutics;Sclerosis;2024-06-27

5. Localized Colitis Associated With Cholecystectomy in Multiple Sclerosis Patient Treated With Ocrelizumab;Cureus;2024-05-30